24, the OFA described the decision as reckless and arbitrary and said it will deprive patients of a vital treatment for type 2 diabetes, obesity, cardiovascular disease and other serious medical conditions. The group also alleged that significant issues remain with the supply of these drugs, saying FDA officials acted to benefit special interests. If ever an agency action were arbitrary, capricious, and contrary to law, this is it, the OFA added in its lawsuit
Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits
GHK-Cu introduces copper-binding peptide activity associated with extracellular matrix communication and connective tissue signaling
Common issues include nausea, vomiting, and gastrointestinal discomfort
doi: 10.1053/j.gastro.2016.01.032 48
Medication tracking apps provide reminders and create a log you can reference